CRISPR Therapeutics
The company develops gene-based medicines using CRISPR/Cas9 technology to treat serious diseases including sickle cell disease, beta thalassemia, and various cancers. Its portfolio includes the approved therapy CASGEVY and multiple clinical programs focused on immuno-oncology, autoimmune disorders, and regenerative medicine. The firm targets patients with chronic genetic conditions and utilizes both ex vivo and in vivo gene editing approaches.
Biotechnology
Healthcare
Gene Editing
Oncology
Pharmaceuticals
Funding summary
- Total raised
- €115.2M
- Funding rounds
- 3
Investors in CRISPR Therapeutics
Investors on record for CRISPR Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like CRISPR Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors